BMY vs KARD: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
BMY is the larger of the two ($121.58B market cap): the incumbent the market prices for continued execution (8.88x forward earnings, beta 0.19). KARD is the smaller challenger ($1.12B), still expected to post a loss next year: more room to run, but more to prove. If the story you believe is BMY's (New product portfolio ramp), BMY is the more direct way to own it; if it is KARD's (Late-stage cardiovascular pipeline), KARD is.
BMY vs KARD: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BMY | KARD | What it tells you |
|---|---|---|---|
| Market cap | $121.58B | $1.12B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 8.88 | -2.88 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Price vs 52-week range | 60% of range | 2% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 5.19 | 1.96 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how BMY and KARD affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BMY and KARD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BMY and KARD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Bristol Myers Squibb (BMY) do?
Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. It makes money primarily by selling patented branded drugs, with a portfolio that has historically leaned on blockbuster franchises such as the blood thinner Eliquis (co-marketed with Pfizer), the cancer immunotherapy Opdivo, and the multiple myeloma drug Revlimid. The company is working through a major patent cliff as several legacy products lose exclusivity, and it is rebuilding growth through a newer portfolio that includes drugs like Reblozyl, Opdualag, Camzyos, Sotyktu, and the schizophrenia treatment Cobenfy (acquired through Karuna). Bristol Myers grows both organically through its research pipeline and through large acquisitions (Celgene, MyoKardia, Karuna, Mirati). It is headquartered in New York and operates worldwide.
What does Kardigan (KARD) do?
Kardigan, Inc. (Nasdaq: KARD) is a clinical-stage precision cardiovascular therapeutics company based in Princeton, New Jersey, founded in 2023 and formerly known as EnCarda. It was created by former executives of MyoKardia, the team behind mavacamten (Camzyos), the hypertrophic cardiomyopathy drug that led to Bristol Myers Squibb's roughly $13 billion acquisition of MyoKardia. Kardigan is developing three late-stage candidates that target the underlying biology of specific heart conditions where treatments are limited: danicamtiv (a cardiac myosin activator in-licensed from BMS) for genetic dilated cardiomyopathy, ataciguat for calcific aortic valve stenosis, and tonlamarsen for acute severe hypertension. It pairs these programs with the Prolaio AI and real-world-data platform, branded as Cardiac Intelligence, to sharpen trial design.
BMY vs KARD: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- BMY drivers: New product portfolio ramp; Oncology and immunology depth.
- KARD drivers: Late-stage cardiovascular pipeline; MyoKardia pedigree and BMS-sourced asset.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. For KARD, kardigan is pre-revenue and deeply loss-making, so its value depends on clinical trial outcomes that remain years away and could fail.
BMY or KARD: which should you pick?
With growth, valuation and volatility this close (or not yet reported for one side), the drivers above are what separate BMY from KARD. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BMY and KARD guides.
BMY vs KARD: the full fundamentals
BMY. At about $59.43 on November 20, 2026, Bristol Myers trades near 9 times forward earnings, still low relative to large-cap pharma peers, which reflects market skepticism about replacing patent-cliff revenue even after a fifth straight earnings beat in Q3. The 4.3% dividend yield and strong cash flow are the bull-case anchors, while consensus for only modest 2027 EPS growth (about $6.70 versus $6.45 for 2026) on lower revenue captures the bear case. The 24 analysts in Yahoo's consensus carry a mean target near $65.
KARD. Kardigan generates no product revenue and funds a growing research budget, producing a net loss of about $58.6 million in Q3 2026 (reduced by a $21.8 million milestone fair-value benefit) and roughly $287 million over the trailing twelve months. Its valuation reflects pipeline potential, not current financials: at about $1.13 billion, the market cap is roughly 1.9 times the ~$591 million of cash, so investors are assigning around $540 million to three mid- and late-stage programs whose main readouts now fall between the second quarter and the second half of 2027. Analysts expect a loss of about $4.53 per share for 2026 and $4.17 for 2027.
Headline figures (approximate, November 2026): BMY shows revenue (ttm) ~$50.0 billion (Q3 2026 up ~6.9% YoY), q3 2026 adjusted eps $1.35 vs $1.17 consensus, operating margin ~32%, net income (ttm) ~$9.2 billion; KARD shows revenue (ttm) ~$0 (pre-commercial), net loss (ttm) ~-$287M, net loss (q3 2026) ~-$58.6M (incl. ~$21.8M milestone fair-value benefit), eps (q3 2026) -$0.64 vs ~-$1.04 expected.
The bottom line: BMY vs KARD
BMY and KARD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined BMY and KARD exposure against your real portfolio. It is not an investment adviser.
Wondering how BMY or KARD fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Bristol Myers Squibb
Ask Walnut's AI anything about BMY and see how it fits what you own.
FAQ
What is the difference between BMY and KARD?
+
Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. Kardigan, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BMY or KARD the better stock?
+
Neither is universally better. BMY is the larger incumbent; KARD is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BMY or KARD?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BMY and KARD?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BMY vs KARD?
+
BMY: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. Revlimid has already declined under generic entry. The newer portfolio must scale fast enough to offset these losses, which is not guaranteed, and consensus already pencils in lower revenue in 2027, with EPS up only about 4%. Drug pricing pressure (including US Medicare negotiation under the Inflation Reduction Act, which named Eliquis), clinical trial failures, regulatory setbacks, and integration risk from large acquisitions all weigh on the outlook; the split admilparant readout in October 2026, which also came with protocol changes and a patient death the company said was likely unrelated, is a reminder of how quickly pipeline news can move the stock. Debt of about $45 billion against about $12.6 billion of cash, and litigation exposure, add further uncertainty. KARD: Kardigan is pre-revenue and deeply loss-making, so its value depends on clinical trial outcomes that remain years away and could fail. Its S-1 disclosures included going-concern language tied to pre-IPO cash, and while the IPO extended the runway into 2028, the company will likely need to raise more capital and could dilute shareholders. Any negative or delayed data from danicamtiv, ataciguat, or tonlamarsen could sharply reduce the stock, and a post-IPO lock-up expiration may add selling pressure. The shares have already shown that volatility: they fell below the $16.00 IPO price and closed near $12.04 on November 20, 2026, about 42% lower over three months. The November 2026 decision to read ataciguat at week 48 and the slower tonlamarsen enrollment push two of three readouts into the second half of 2027, extending the wait and the cash burn before the main catalysts. Contingent milestone liabilities tied to in-licensed assets can also swing reported losses in both directions, as a $43.5 million fair-value charge in the second quarter of 2026 and a $21.8 million benefit in the third showed. It also competes with larger, better-capitalized cardiovascular players.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BMY or KARD; figures are approximate and dated (as of November 2026). Verify current data before investing.